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SUMMARY 
Background: A new generation of antipsychotics was introduced over a decade ago for the 
treatment of schizophrenia. However, despite a multitude of studies, their purported clinical 
superiority is still a matter of debate. This may be partly due to the short duration, 
restrictive inclusion criteria, and inappropriate outcome measures used in most studies. 
Pragmatic trials can overcome these limitations. 
Methods: This multinational study including 50 sites in 14 countries examined 
effectiveness, operationalised as continued use of the allotted medication, of the second 
generation antipsychotics, amisulpride, quetiapine, olanzapine, and ziprasidone in first 
episode schizophrenia with minimal prior exposure to antipsychotic treatment over a one-
year period, in a pragmatic, randomized, open design. The dose of the comparator, 
haloperidol, was maximized at 4 mg daily. Cox proportional-hazards regression models 
were used to calculate differences between haloperidol and the four new antipsychotics with 
adjustments for gender and country. 
Findings: 498 patients enrolled, 40% were female and 33% were antipsychotic naive at 
randomization. The mean daily doses were 2.9 mg for haloperidol, 449 mg for amisulpride, 
12.5 mg for olanzapine, 501 mg for quetiapine, 114 mg for ziprasidone. Haloperidol was 
discontinued prematurely in 61% of patients, while discontinuation was significantly less 
common on olanzapine (HR 0.27; p<0.001), amisulpride (HR 0.36; p<0.001), quetiapine 
(HR 0.49; p<0.001), and ziprasidone (HR 0.47; p=0.002). 
Interpretation: Continuation rates on several of the second generation antipsychotics in 
this pragmatic trial were high, suggesting that effective and clinically meaningful long-term 
antipsychotic treatment is achievable in the first stages of schizophrenia. 
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INTRODUCTION 
A new generation of antipsychotics was introduced over a decade ago with the goal of 
combining superior efficacy with a diminished propensity to induce (motor) side-effects in 
the treatment of schizophrenia. However, despite a multitude of studies, their purported 
clinical superiority is still a matter of debate.1-5 Indeed, as has been recently argued 
convincingly, the conclusions that can be drawn from the efficacy studies is limited.6 Most 
studies used restrictive inclusion criteria, leading to overrepresentation of males and under-
representation of drug-abusing patients and those with co-morbid illness. Moreover, treatment 
response in these efficacy studies is almost exclusively based on reductions in psychosis 
rating scales, capturing only one, and arguably not the most relevant, outcome measure in 
schizophrenia. Finally, studies have generally been shorter than two months which may not 
be appropriate for an illness potentially lasting a lifetime.6-8 
It has been suggested by us and others that there is a dire need for studies that are 
unrestrictive in the inclusion of patients, use long follow-up periods and employ clinically 
meaningful outcome measures.6,7 One such outcome is the time patients continue to use their 
allotted study medication, capturing as it does both efficacy and tolerability, called 
effectiveness, of the medicines studied. Interestingly, retainment in treatment trials in 
schizophrenia is very low, usually less than 50-60%, even in short-term studies. Although this 
may be in part attributable to the presence of a placebo group in some of those studies9 large 
drop-out rates are a common feature of all antipsychotic efficacy trials in schizophrenia. It has 
been argued that the large drop-out rate may in part be due to the double-blind design 
common to most efficacy studies. Moreover, although double-blind studies carry obvious 
advantages in reducing bias, a disadvantage is that due to their very nature they do not reflect 
clinical practice. A solution is the pragmatic trial; this method aims to reflect clinical practice 
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by including unselected patient samples in a randomized, but open, design. Indeed, it has 
recently been proposed that it is this kind of studies that need to be conducted to test 
antipsychotic effectiveness in schizophrenia, particularly in the first stages of the illness.5,6 
Examining effectiveness of the newer antipsychotic drugs is particularly relevant in the early 
stages of schizophrenia.7 Evidence is abundant that continued treatment is not only 
paramount in preventing relapse but that psychotic recurrences lead to poorer subsequent 
treatment response with rates of response declining and time to response increasing.4,10 
Moreover, it has been shown that antipsychotic treatment may limit the progression in brain 
loss observed in schizophrenia.11,12 Thus, whether patients will continue using their 
medication from the moment of first treatment carries long-term consequences for the 
subsequent course of their illness. This is particularly relevant in the early stages of the 
illness, since most of the functional decline takes place during that period of the illness 
(Häfner et al. 1995, for review Riecher-Rössler et al. 2006).  
A question that can only be addressed in first-episode schizophrenia is antipsychotic 
effectiveness in patients that have never, or hardly, been exposed to prior treatment with 
antipsychotics. Indeed, antipsychotic effectiveness in drug-naïve patients may be quite 
different from that found in patients who have been exposed to (various) antipsychotics for 
years or even decades. One of the reasons may be biological, i.e. dopamine receptor 
sensitivity is most likely substantially different in patients who have had no prior exposure to 
the dopamine antagonistic effects of antipsychotics than in chronically treated patients.13 
Another reason may be methodological: trials in chronic patients often involve patients who 
are included for the very reason that they failed to respond adequately to, or were non-
compliant with, previous treatment(s).  
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This study examined effectiveness of several second generation antipsychotics (SGA) in first 
episode schizophrenia with minimal prior exposure to antipsychotic treatment. The dose of 
the comparator, haloperidol, was maximized at 4 mg daily, since it has been shown that first-
episode patients respond to low doses of antipsychotics.14,15 Furthermore, higher doses do not 
increase its antipsychotic effect but do enhance the risk of side effects, especially in first-
episode patients.16-21 
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METHODS 
Setting and participants 
The study’s design has been described previously in more detail.7 Before the start of the trial, 
investigators were trained in the research procedures and the assessments of outcomes, 
including the use of video tapes. A total of 50 sites participated in 13 European countries and 
Israel (see Appendix). Eligible patients were 18-40 years of age and met DSM IV criteria for 
schizophrenia, schizophreniform, or schizoaffective disorder confirmed by the Mini 
International Neuropsychiatric Interview Plus (MINI+).22 Patients were excluded if: (1) more 
than two years had elapsed between onset of positive symptoms and recruitment; (2) any 
antipsychotic had been used for longer than two weeks in the previous year or for more than a 
total of six weeks lifetime; (3) patients had a known intolerance to one of the study drugs; (4) 
patients met any of the contraindications for any of the study drugs as mentioned in the 
(local) package insert texts. The in- and exclusion criteria were checked by clinical research 
associates according to guidelines on good clinical practice. 
 
Recruitment and randomization 
The treating physicians informed eligible patients orally and in writing on the trial and invited 
them to participate. Baseline data were obtained between four weeks before and one week 
after randomization on demographics, diagnoses, current treatment setting, psychopathology 
(Positive and Negative Syndrome Scale – PANSS)23; severity of illness (Clinical Global 
Impression scale – CGI)24; overall psychosocial functioning (Global Assessment of 
Functioning scale – GAF)25,26; extrapyramidal symptoms (EPS; St Hans Rating Scale – 
SHRS)27; and sexual dysfunction (selected items from the Udvalg for Kliniske Undersøgelser 
 9
– UKU)28. Furthermore, we performed a physical examination including assessments of 
laboratory data, weight, height, and ECG. 
Patients were randomized online to one of the five treatment arms. Since some study drugs 
were not registered in all participating countries, the minimization procedure was applied to 
prevent unequal group sizes at the end of the trial, i.e. treatment assignment of new patients 
depended on the distribution of participants over the treatment arms.29 However, 
randomization to ziprasidone was blocked between December 2003 and October 2004 
because this procedure assigned ziprasidone to too high numbers of new patients in the few 
countries where ziprasidone was available. Ziprasidone was randomized again when it 
became available in more participating countries. This procedure explains the different group 
sizes (figure 1). 
All participants – or their legal representative – gave written informed consent. The trial 
complied with the Declaration of Helsinki and the ethics committees of the participating 
centers approved the procedures followed. 
 
Intervention 
Patients were randomly assigned to the following drugs: amisulpride 200-800 mg/d, 
olanzapine 5-20 mg/d, quetiapine 200-750 mg/d, ziprasidone 40-160 mg/d, and haloperidol 1-
4 mg/d. All study medication was administered orally within the dose ranges at the treating 
physician’s discretion. Mood stabilizers, benzodiazepines, antidepressants, and 
anticholinergics were allowed and documented. 
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Outcome assessment 
The primary outcome, Loss of Retention (LOR), was defined by the use – during more than 
14 days over a 6-months interval – of: (1) either a dose below the indicated range or complete 
discontinuation of the study medication, or (2) a dose above the predefined range, or (3) 
another antipsychotic. The use of any parenteral antipsychotic constituted a LOR-event when 
it was active for more than 14 days over a 6-months interval; or – in case of multiple 
parenteral administrations – the active days exceeded 14 days over this interval 
Secondary outcomes were: specified reason for a LOR-event (i.e. lack of efficacy, side 
effects, nonadherence, or other reasons). Data collection of one or more of the following 
secondary outcomes was targeted at 2 weeks (± 1 week), 4 weeks (idem), 6 weeks (idem), 2 
months (idem), 3 months (idem), 6 months (± 1 month), 9 months (idem), and 12 months 
(idem): psychopathology (PANSS), severity of illness (CGI), treatment setting, psychiatric 
hospitalization days, serious adverse events, extrapyramidal syndromes (SHRS), sexual 
dysfunction (selected items of the UKU), weight, local laboratory data, ECG, and 
concomitant medications. We also assessed psychosocial functioning, depression, quality of 
life, clinical and social needs, substance abuse, compliance, and some neurocognitive 
functions. Due to space restrictions results on these measures will be published separately. 
 
Sample size determination 
On the basis of prior studies we assumed a LOR-event rate at 12 months after enrolment of 
70% in patients treated with haloperidol and 40% in patients treated with SGAs. A sample 
size of 310 patients was needed based on a two-tailed test (α= 5%), a power of 80%, and 
Bonferroni corrections for each comparison between the SGAs versus haloperidol. However, 
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since the actual difference may be smaller because of the use of a low dose of haloperidol, we 
planned to enroll 500 patients, i.e. 100 patients per group. 
 
Data analysis 
Following the intention-to-treat principle, all patients randomized were analyzed in the 
assigned treatment group, including patients who did not take any dose of the assigned study 
medication. Following our definition of Loss of Retention (LOR) patients were not at risk 
within the first 2 weeks after randomization. Consequently, these 2 weeks were not included 
in the ‘time-to-event’ (time-to-LOR) analysis. We used Kaplan-Meier methods to estimate 
the time to the LOR event. 
After clustering countries with 15 or fewer patients, Cox proportional-hazards regression 
models were used to estimate differences between haloperidol and the 4 atypicals with 
adjustments for gender and country. Differences were expressed in hazard ratios (HRs) with 
corresponding 95% confidence intervals (CIs) and p values. For the secondary analyses we 
calculated these differences between the four newer antipsychotics and, additionally, we 
assessed these differences per specific reason why patients had a LOR event, for: lack of 
efficacy, side effects, or nonadherence. Since investigators could indicate more than one 
reason for the LOR-event, we decided to rank the options as follows - in order of decreasing 
importance: lack of efficacy according to the investigator, side effects according to the 
investigator, patient initiated nonadherence, and other reasons. 
A multilevel linear mixed-effects model was used to account for the repeated measures of the 
secondary end points PANSS and CGI score.30,31 The model was specified in terms of fixed 
effects for treatment group, time, the PANSS or CGI score at baseline, gender and country. 
We also studied the interaction between treatment group and time. To assess the linearity of 
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PANSS and CGI scores across the study measurements, time squared terms were included in 
the model. The dependent variable was PANSS or CGI score. Random effects within the 
model were intercept and slope for individual patients. For tests of statistical significance, 
variability was assessed within treatment groups with the patient being the unit of 
observation. For the analyses of secondary outcomes (PANSS, CGI, and safety/tolerability 
data), data were limited to those assessed before a LOR event occurred. Because of high 
numbers of extreme outliers, we disregarded all prolactin values from three sites (values 
exceeded 10 U/L) and all insulin values from one site (values exceeded 200 mU/L). 
All statistical tests were two-sided and p values less than 0.05 were considered significant.  
 
Role of funding sources 
This study was funded through the European Group for Research in Schizophrenia (EGRIS) 
which in turn received funding from three pharmaceutical companies that had no role in the 
study design, data collection, data analysis, data interpretation, writing of the report, or the 
decision to submit the paper for publication. Representatives of the industries were nonvoting 
members of the steering committee.7 
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RESULTS 
Subjects 
Patients were screened between December 2002 and January 2006. The available data show 
that 1047 patients were screened of whom 406 patients were not eligible, 143 patients were 
not randomized (121 patients declined informed consent), and 498 patients were randomized 
to one of the treatment arms (figure 1). Table 1 shows that the groups were well matched. The 
mean age was 26.0 years. Of the 498 patients enrolled, 200 (40%) were female, 197 (40%) 
had schizophreniform disorder, and 162 (33%) were antipsychotic naive at randomization. 
Between randomization and the end of the follow-up some enrolled patients were not eligible: 
11 patients (4 on haloperidol, 2 on olanzapine, 2 on quetiapine, and 3 on ziprasidone) turned 
out to have another cause for the symptoms than schizophrenia; one patient on quetiapine had 
symptoms for more than two years prior to randomization; and two patients on amisulpride 
used antipsychotics for more than two weeks in the previous year. Following the intention-to-
treat-principle these patients were included in the analysis. The mean daily doses were 2.9 mg 
for haloperidol, 449 mg for amisulpride, 12.5 mg for olanzapine, 501 mg for quetiapine, 114 
mg for ziprasidone (Table 2). 
 
Primary outcome 
Table 2 and figure 2a show that time to the LOR event for any cause was significantly shorter 
in patients on haloperidol than on any of the four SGAs: olanzapine (HR 0.27; p<0.001), 
amisulpride (HR 0.36; p<0.001), quetiapine (HR 0.49; p<0.001), and ziprasidone (HR 0.47; 
p=0.002). Also, as a group the SGAs showed a longer time to the LOR event compared to 
haloperidol (HR 0.39; 95% CI 0.29-0.53; p<0.001; results not presented in a table or figure).  
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Secondary outcomes 
Loss of Retention 
The SGAs did not differ from each other on time to LOR for any cause, except that patients 
on olanzapine stayed longer on their assigned study drug than those on quetiapine (HR 0.50; 
p<0.01).  
Comparing time to LOR because of lack of efficacy (figure 2b and table 2) showed that 
patients on haloperidol dropped out sooner than those on olanzapine (HR 0.17; p<0.001), 
amisulpride (HR 0.22; p<0.001), and ziprasidone (HR 0.51; p=0.04) but not quetiapine 
(p=0.13). Also, analyzing the time to treatment discontinuation between the SGAs revealed 
that patients stayed longer on olanzapine (HR 0.26; p<0.001) and on amisulpride (HR 0.36; 
p<0.01) than on quetiapine.  
The time to a LOR event because of side effects (figure 2c and table 2) in the haloperidol 
group was shorter than in the quetiapine group (HR 0.12; p<0.01) and the olanzapine group 
(HR 0.23; p<0.01).  
Finally, table 2 and figure 2d show that patients on haloperidol did not differ in time to the 
LOR event due to antipsychotic non-adherence. 
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PANSS 
The decrease of the total PANSS score was statistically significant in all treatment groups 
(p<0.001; Figure 3). After circa six months the change in PANSS total scores compared with 
baseline leveled off. Compared with haloperidol, the other four medications showed a lower 
PANSS score after 12 months of treatment (56.0, 54.2, 53.8, 51.4, and 53.7 for haloperidol, 
olanzapine, quetiapine, amisulpride and ziprasidone, respectively). 
 
CGI 
All treatment groups showed statistically significant reductions on the CGI compared to 
baseline (p<0.001). 
 
Safety and tolerability 
Table 3 shows the outcomes of safety and tolerability. Two patients died during the follow up 
(suicide). About 20% of the patients were admitted to hospital after randomization, but the 
proportions did not differ significantly for the five groups. 
Differences were found on the prevalence of neurological side effects: higher proportions of 
patients on haloperidol or ziprasidone experienced akathisia as compared with patients on the 
other antipsychotics (26-28% vs. 10-16%; p<0.01) and more patients on haloperidol showed 
signs of Parkinsonism than patients assigned to any of the SGAs (34% vs. 6-17%; p<0.001). 
Though the proportions of patients being overweight were high (34-54%) and did not differ 
between treatment arms, weigh gain (>7% from baseline) and weight change (overall and per 
month) were highest for patients on olanzapine and lowest for patients on haloperidol or 
ziprasidone (e.g. 86% on olanzapine showed >7% weight gain vs. 39-53% for the other drugs 
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[p<0.001]; +1.7 kg/month on olanzapine vs. +0.8-1.0 kg/month for the other drugs 
[p<0.001]). 
We found no differences between treatment arms on fasting glucose, cholesterol, high- and 
low-density lipoprotein, fasting insulin, and triglycerides, except for 89% of patients on 
amisulpride having hyperprolactinemia, versus 41-50% in patients on other antipsychotics 
(p<0.001), and amisulpride showing greater increases in prolactin values per month (p<0.001; 
data not shown in table). 
High proportions of patients used concomitant medication with more patients on haloperidol 
or olanzapine taking antidepressants (15-18% vs. 6-7%; p<0.01). Additionally, higher 
proportions of patients on haloperidol or amisulpride received anticholinergics (28-36% vs. 
17-21%; p<0.01) than the other patients. 
 
Post-hoc analyses 
Comparing males and females revealed no differences in time to the LOR event. 
Additionally, analyses excluding patients who did not take the assigned antipsychotic or who 
- after all - did not meet the inclusion criteria did not change the results.  
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DISCUSSION 
The main finding is that effectiveness, expressed as continued use of the assigned study 
medication, of SGAs was significantly greater than that of a low dose of haloperidol in first-
episode schizophrenia and schizophreniform patients. This superior effectiveness could be 
attributed to both the improved therapeutic efficacy and better tolerability of olanzapine; 
larger therapeutic efficacy of amisulpride and ziprasidone; and superior tolerability of 
quetiapine as compared to haloperidol. The overall discontinuation rate varied widely, from 
61% for haloperidol to 28% for olanzapine. Patients who completed the entire study on their 
allotted medication did equally well symptomatically at the end of the 12 months follow-up.  
About 20% of all patients were (re)admitted to hospital during the follow-up period, but this 
percentage was not different for the study drugs. Side-effects varied: haloperidol showed 
more Parkinsonism than the SGAs, while weight gain was most pronounced in patients on 
olanzapine, and lowest on those on haloperidol and ziprasidone. A higher proportion of 
patients on haloperidol and amisulpride was prescribed anticholinergic medication. 
This is the first study comparing long-term effectiveness of various SGAs with that of a first-
generation antipsychotic in a large group of unselected first-episode schizophrenia patients. 
Indeed, 40% of the patients at baseline were diagnosed as schizophreniform, and a third had 
never been exposed to prior antipsychotic treatment. Exceptionally for most antipsychotic 
treatment trials, 40% of the sample was female, reflecting as it does the male to female 
distribution of this illness in the population.32 Finally, consistent with the unrestrictive 
inclusion criteria, a quarter of the patients exhibited suicidal thoughts, 9% suffered from co-
morbid depression and almost one in five met criteria for current substance dependence or 
abuse. Therefore, it is difficult to compare its results to those of earlier studies.  
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One large study (n=555) compared the effects of risperidone (modal dose 3.3 mg), a SGA, to 
a low dose of haloperidol (2.9 mg) in a double blind randomized design. Primary outcome 
was number of relapses, but discontinuation rates were also reported, and were not 
significantly different for the two groups, i.e. around 36.5% for haloperidol, and 42% for the 
risperidone group. However, patients with drug (ab)use and concomitant medications were 
excluded and prior antipsychotic treatment was allowed for up to 12 weeks. Nevertheless 
these results may suggest that under double-blind conditions dropout rates on haloperidol 
may be lower than in our study. Similar to our results, akathisia and parkinsonism were more 
pronounced on haloperidol than on the SGAs.15 
In another double-blind study in 263 first-episode schizophrenia patients haloperidol (modal 
dose 4.8 mg) was compared to olanzapine (10.2 mg) over a two year follow-up period. This 
sample was predominantly male (82%) and prior treatment was maximized at 16 weeks. Drug 
abuse was excluded. In this study, estimated discontinuation rates at one year (data 
extrapolated) were considerably higher than in our study: approximately 75% for the 
haloperidol group and around 65% for olanzapine, with a significantly larger group 
continuing treatment on olanzapine than on haloperidol at two years.33 
Low completion rates of around 30% were also found in a one-year study comparing 
effectiveness, defined as completion rates on the assigned drug, between three SGAs 
(olanzapine, quetiapine and risperidone, n=400) in patients in the early course of 
schizophrenia. In contrast to our findings, discontinuation rates did not differ among the 
compounds tested.34 Whether the large difference in discontinuation rates between studies can 
solely be explained by the difference in open versus double blind design remains open to 
debate. 
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In chronic schizophrenia, effectiveness of SGAs has been compared to that of the low 
potency first-generation antipsychotic, perphenazine. In that study, 1493 chronic 
schizophrenia patients were randomized to olanzapine, quetiapine, risperidone, ziprasidone 
and perphenazine.8 Similar to the results in our study, olanzapine was found superior in 
effectiveness as compared to quetiapine (and versus risperidone, which was not tested in this 
study). Also consistent with our results, when lack of efficacy was the reason for 
discontinuation, time to discontinuation was longer in the olanzapine group than in the 
patients on perphenazine and quetiapine but, as we found, similar to that of ziprasidone. In 
contrast to that study, overall discontinuation rates in our study were considerably lower, 
even when groups are compared with the lowest discontinuation rates in both studies: in our 
study 28% of patients on olanzapine discontinued treatment within a year versus 64% in the 
other study. It could be argued that this difference may be due to the patient groups studied, 
since first-episode patients respond better and faster than chronic patients. Also, patients in 
our study were unlikely to have failed prior treatments (since their prior exposure in the year 
prior to enrolment was maximized at two weeks), whereas in the study in chronic patients this 
may have been a reason for inclusion.  
It could be argued that results of our study are biased by the open nature of the design. 
Physicians could have been motivated to discontinue patients on haloperidol earlier than 
when the study would have been double-blind. However, such a bias contrasts with the high 
rates of first-generation antipsychotics still being prescribed in Europe. The discontinuation 
on the patients on haloperidol and quetiapine due to lack of efficacy occurred mostly within 
the first two months of the study. Whether this is attributable to investigator bias or to a lack 
of efficacy early in the treatment, or dosing issues, remains unclear. 
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Interestingly, even though haloperidol was given in a low dose it induced Parkinsonism more 
than the SGAs; also more patients were prescribed anticholinergic medication while on 
haloperidol than patients on olanzapine and quetiapine. Indeed, the side-effects observed in 
this study are generally consistent with those published in other studies and meta-analyses 
with weight gain most pronounced in patients on olanzapine and least in those on haloperidol 
and ziprasidone. Interestingly, dystonia was hardly observed, even in the haloperidol group, 
suggesting that the low dose used in this study is well-tolerated in this regard. 
In conclusion, this study found that one year discontinuation rates in an unselected sample of 
first-episode schizophrenia patients varied widely (between 28 and 61%) and were 
significantly larger on a low dose of haloperidol than on several of the SGAs. This effect 
could be explained by improved efficacy and tolerability of olanzapine, increased efficacy of 
amisulpride and ziprasidone and better tolerability of quetiapine. If patients continued their 
medication they did equally well on all drugs. Encouragingly, in contrast to most earlier 
studies in first-episode and chronic schizophrenia, continuation rates on several of the SGAs 
in this pragmatic trial were high (around 70%) suggesting that effective and clinically 
meaningful long-term antipsychotic treatment is achievable in the first stages of 
schizophrenia. 
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TABLES AND FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Trial profile 
Randomisation to Ziprasidone was blocked between December 2003 and October 2004. Patients 
who dropped out within 14 days have not been at risk for a Loss of Retention event. 
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 (5 within 2 
 weeks)  
 33 withdrew  
  consent/no 
  show  
 0 other  
  reason 
 82 completed 
 follow up 
 23 dropped out
 (3 within 2 
 weeks) 
 21 withdrew  
  consent/no 
  show 
 2 other  
  reason 
 70 completed 
 follow up 
 34 dropped out
 (4 within 2 
 weeks) 
 31 withdrew  
  consent/no 
  show  
 3 other  
  reason 
 53 completed 
 follow up 
 29 dropped out
 (5 within 2 
 weeks) 
 25 withdrew  
  consent/no 
  show  
 4 other  
  reason 
1047 patients screened 
406 did not meet 
 inclusion criteria 
Mean 4.5 (4.7 sd) 
months follow up 
for sec. analyses 
Mean 7.0 (4.9 sd) 
months follow up 
for sec. analyses 
Mean 8.4 (4.6 sd) 
months follow up 
for sec. analyses 
Mean 6.3 (5.0 sd) 
months follow up 
for sec. analyses 
Mean 6.0 (5.0 sd) 
months follow up 
for sec. analyses 
104 assigned to 
 quetiapine 
 2 did not take 
  drug 
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Table 1 Baseline characteristics of patients* 
 
 
Haloperidol 
(N=103) 
Amisulpride 
(N=104) 
Olanzapine 
(N=105) 
Quetiapine 
(N=104) 
Ziprasidone 
(N=82) 
Total  
(N=498) 
Sociodemographic characteristics       
 Mean age (SD) 25.4 (5.6) 25.2 (4.9) 26.3 (5.9) 26.4 (5.7) 26.7 (5.7) 26.0 (5.6) 
 Women 39/103 (38%) 46/104 (44%) 38/105 (36%) 36/104 (35%) 41/82 (50%) 200/498 (40%) 
 Caucasian 93/103 (90%) 102/104 (98%) 100/105 (95%) 97/104 (93%) 77/82 (94%) 469/498 (94%) 
 Mean years of education (SD)1 12.4 (2.5) 12.8 (2.9) 12.7 (3.4) 12.0 (2.9) 12.4 (2.6) 12.5 (2.9) 
 Living alone 14/100 (14%) 12/104 (12%) 12/104 (12%) 20/104 (19%) 8/81 (10%) 66/493 (13%) 
 Employed (includes students) 42/101 (42%) 55/104 (53%) 46/105 (44%) 46/104 (44%) 42/82 (51%) 231/496 (47%) 
Diagnosis2       
 Schizophreniform 36/103 (35%) 42/104 (40%) 35/105 (33%) 38/104 (37%) 47/82 (57%) 198/498 (40%) 
 Schizoaffective 8/103 (8%) 5/104 (5%) 9/105 (9%) 8/104 (8%) 5/82 (6%) 35/498 (7%) 
 Schizophrenia 59/103 (57%) 57/104 (55%) 61/105 (58%) 58/104 (56%) 30/82 (37%) 265/498 (53%) 
Depression (current)2 9/97 (9%) 5/103 (5%) 9/103 (9%) 17/103 (17%) 6/81 (7%) 46/487 (9%) 
Suicidality (current)2 20/98 (20%) 23/104 (22%) 29/103 (28%) 29/103 (28%) 17/81 (21%) 118/489 (24%) 
Alcohol dependence/abuse (current)2 10/98 (10%) 3/104 (3%) 15/103 (15%) 12/103 (12%) 8/81 (10%) 48/489 (10%) 
Substance dependence/abuse 
(current)2 
18/98 (18%) 14/104 (13%) 18/103 (17%) 23/103 (22%) 15/81 (19%) 88/489 (18%) 
Inpatient 87/103 (84%) 97/104 (93%) 101/105 (96%) 89/104 (86%) 71/82 (87%) 445/498 (89%) 
Antipsychotic naive 36/103 (35%) 44/104 (42%) 25/105 (24%) 40/104 (38%) 17/82 (21%) 162/498 (33%) 
Mean psychopathology - PANSS 
(SD)3 
      
 Total 88.9 (19.8) 86.4 (19.2) 87.6 (21.1) 91.5 (22.6) 88.3 (20.1) 88.5 (20.6) 
 Positive scale 22.8 (5.6) 23.0 (6.1) 23.1 (6.3) 23.7 (6.7) 23.0 (6.3) 23.1 (6.1) 
 Negative scale 21.5 (7.9) 20.3 (7.2) 21.1 (6.9) 22.0 (7.4) 21.3 (8.8) 21.2 (7.6) 
 General psychopathology scale 44.5 (9.7) 43.1 (10.1) 43.4 (11.4) 45.8 (12.3) 43.9 (9.9) 44.1 (10.8) 
Mean severity of illness - CGI (SD)4 4.9 (0.7) 4.8 (0.8) 4.8 (0.8) 4.9 (0.8) 4.8 (0.8) 4.8 (0.8) 
Mean overall functioning - GAF 
(SD)5 
38.6 (12.2) 40.3 (12.5) 43.0 (15.1) 38.8 (14.2) 39.3 (12.9) 40.0 (13.5) 
Extrapyramidal symptoms – SHRS6       
 Akathisia 15/99 (15%) 8/104 (8%) 8/104 (8%) 10/102 (10%) 8/81 (10%) 49/490 (10%) 
 Dystonia 2/99 (2%) 3/104 (3%) - 1/102 (1%) 3/81 (4%) 9/490 (2%) 
 Parkinsonism 13/99 (13%) 11/104 (11%) 6/104 (6%) 8/102 (8%) 15/81 (19%) 53/490 (11%) 
 Dyskinesia 1/99 (1%) 1/104 (1%) - - 1/81 (1%) 3/490 (1%) 
Sexual dysfunction – UKU7       
 Men 15/61 (25%) 14/57 (25%) 15/65 (23%) 15/67 (22%) 13/41 (32%) 72/291 (25%) 
 Women 10/36 (28%) 11/46 (24%) 9/38 (24%) 11/33 (33%) 7/39 (18%) 48/192 (25%) 
Weight8       
 Overweight (BMI ≥25) 20/96 (21%) 11/101 (11%) 17/104 (16%) 20/102 (20%) 16/81 (20%) 84/484 (17%) 
 Mean BMI (SD) 22.3 (3.5) 21.7 (3.6) 22.0 (3.0) 22.7 (3.3) 22.5 (3.8) 22.2 (3.4) 
Prolonged QTc interval9 2/97 (2%) 5/98 (5%) 4/99 (4%) 2/96 (2%) 1/74 (1%) 14/464 (3%) 
* Denominators fluctuate due to differences in response. Because of rounding, proportions may not sum up to 100. 
1
 Years in school from 6 years of age onwards. 
2
 According to the Mini International Neuropsychiatric Interview Plus (MINI+); ‘Depression’ includes ‘major depressive episode (with or without 
melancholic features)’ and ‘dysthemia’. 
3
 Positive and Negative Syndrome Scale (PANSS); theoretical scores range from 30-210 (total scale), 7-49 (positive scale), 7-49 (negative scale), 16-
112 (general psychopathology scale); higher scores indicate more severe psychopathology. 
4
 Clinical Global Impression (CGI); theoretical scores range from 1-7; higher scores indicate greater severity of illness. 
5
 Global Assessment of Functioning (GAF); theoretical scores range from 1-100; higher scores indicate better functioning. 
6
 St Hans Rating Scale (SHRS). 
7
 Cases scored moderate/severe on selected items of the Udvalg for Kliniske Undersøgelser (UKU); for men: increased/decreased libido, orgastic 
dysfunction, gynaecomastia, or erectile/ejaculatory dysfunction (6 items); for women: increased/decreased libido, orgastic dysfunction, menorrhagia, 
amenorrhoea, galactorrhoea, or dry vagina (7 items). 
8
 Body Mass Index (kg/m2); Interquartile Range. 
9
 QTc prolongation: men >450 mseconds, women >470 mseconds 
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Figure 2a Time to LOR-event for any reason Figure 2b Time to LOR-event for lack of efficacy 
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Figure 2c Time to LOR-event for side effects Figure 2d Time to LOR-event for non-adherence 
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Table 2 Loss Of Retention (LOR) according to allocated treatment1 
 
 
Haloperidol 
(N=103) 
Amisulpride 
(N=104) 
Olanzapine 
(N=105) 
Quetiapine 
(N=104) 
Ziprasidone 
(N=82) 
P value1 
Mean dose before LOR-event (mg/d, SD) 2.9 (1.2) 448.5 (175.1) 12.5 (4.9) 501.3 (201.4) 114.2 (61.8)  
≥ maximum dose before LOR-event 54/92 (59%) 25/96 (26%) 54/102 (53%) 36/99 (36%) 36/78 (46%) <0.001 
LOR for any cause 63/103 (61%) 32/104 (31%) 29/105 (28%) 50/104 (48%) 30/82 (37%)  
Months to LOR – 25th percentile (95% CI)2 0.5 (0.5-0.9) 5.3 (3.0-12+) 6.4 (3.8-12+) 1.2 (7.0-2.0) 1.1 (0.8-8.5)  
Cox-model treatment comparisons3       
 Haloperidol       
  Hazard Ratio (95% CI)  0.36 (.23-.55) 0.27 (.17-.42) 0.49 (.33-.73) 0.47 (.29-.76) <0.001 
  P value  <0.001 <0.001 <0.001 0.002  
 Quetiapine       
  Hazard Ratio (95% CI)  0.74 (.45-1.19) 0.50 (.33-.87)  0.95 (.57-1.59)  
  P value  0.21 0.01  0.85  
 Amisulpride       
  Hazard Ratio (95% CI)   0.72 (.43-1.22)  1.21 (.69-2.14)  
  P value   0.23  0.51  
 Ziprasidone       
  Hazard Ratio (95% CI)   0.65 (.34-1.25)    
  P value   0.65    
LOR for lack of efficacy 34/103 (33%) 11/104 (11%) 10/105 (10%) 36/104 (35%) 17/82 (21%)  
Cox-model treatment comparisons3       
 Haloperidol       
  Hazard Ratio (95% CI)  0.22 (.11-.45) 0.17 (.08-.34) 0.68 (.41-1.12) 0.51 (.27-0.96) <0.001 
  P value  <0.001 <0.001 0.13 0.04  
 Quetiapine       
  Hazard Ratio (95% CI)  0.36 (.18-.76) 0.26 (.13-.55)  0.83 (.43-1.61)  
  P value  0.01 <0.001  0.58  
 Ziprasidone       
  Hazard Ratio (95% CI)  0.52 (.22-1.23) 0.39 (.15-.98)    
  P value  0.14 0.05    
 Amisulpride       
  Hazard Ratio (95% CI)   0.71 (.29-1.74)    
  P value   0.45    
LOR for side effects 13/103 (13%) 12/104 (12%) 5/105 (5%) 2/104 (2%) 7/82 (9%)  
Cox-model treatment comparisons3       
 Haloperidol       
  Hazard Ratio (95% CI)  0.55 (.25-1.23) 0.23 (.08-.65) 0.12 (.03-.54) 0.45 (.16-1.27) 0.02 
  P value  0.14 0.01 0.01 0.13  
 Amisulpride       
  Hazard Ratio (95% CI)   0.38 (.13-1.11) 0.21 (.05-.99) 0.90 (.30-2.66)  
  P value   0.08 0.05 0.84  
 Ziprasidone       
  Hazard Ratio (95% CI)   0.68 (.18-2.51) 0.26 (.05-1.49)   
  P value   0.56 0.13   
 Olanzapine       
  Hazard Ratio (95% CI)    0.35 (.06-2.00)   
  P value    0.24   
LOR for non-adherence 15/103 (15%) 9/104 (9%) 13/105 (12%) 11/104 (11%) 6/82 (7%)  
Cox-model treatment comparisons3       
 Haloperidol       
  Hazard Ratio (95% CI)  0.52 (.22-1.24) 0.52 (.24-1.12) 0.40 (.17-.91) 0.46 (.16-1.31) 0.27 
  P value  0.14 0.10 0.03 0.14  
 Amisulpride       
  Hazard Ratio (95% CI)   1.01 (.41-2.45) 0.84 (.32-2.18) 0.77 (.25-2.32)  
  P value   0.99 0.72 0.64  
 Ziprasidone       
  Hazard Ratio (95% CI)   1.32 (.45-3.91) 0.91 (.30-2.81)   
  P value   0.61 0.87   
 Olanzapine       
  Hazard Ratio (95% CI)    0.59 (.24-1.46)   
  P value    0.25   
LOR for other reason 1/103 (1%) - 1/105 (1%) 1/104 (1%) -  
1
 Standard Deviation (SD); Confidence Interval (CI). 
2
 Kaplan Meier; months at risk for the LOR event, excluding the first 14 days after randomization. For amisulpride and olanzapine no upper limit for 
the CI could be estimated because of low event rates. 
3
 Cox proportional-hazards regression models, adjusted for gender and country.  
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Figure 3 PANSS total score during 12 months follow up 
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Table 3 Outcomes of safety and tolerability* 
 Haloperidol Amisulpride Olanzapine Quetiapine Ziprasidone P-value 
Psychiatric hospitalisation       
 Patients admitted to hospital after 
randomisation / patients at risk for 
admission 
17/66 (26%) 17/88 (19%) 19/90 (21%) 17/61 (28%) 10/60 (17%) 0.53 
 Number of admissions to hospital 
after randomisation / total patient-
years at risk for admission 
20/34.0 22/52.8 31/62.8  21/38.8 12/35.2  
 Risk ratio 0.59 0.42 0.49 0.54 0.34  
Any serious adverse event 8/103 (8%) 3/104 (3%) 5/105 (5%) 5/104 (5%) - 0.11 
Extrapyramidal symptoms – SHRS1 
      
 Akathisia 19/73 (26%) 15/94 (16%) 10/97 (10%) 11/85 (13%) 19/68 (28%) 0.01 
 Dystonia 1/73 (1%) 3/94 (3%) - 1/85 (1%) 2/68 (3%) 0.44 
 Parkinsonism 25/73 (34%) 16/94 (17%) 6/97 (6%) 9/85 (11%) 11/68 (16%) <0.001 
 Dyskinesia 2/73 (3%) 1/94 (1%) - - - 0.19 
Sexual dysfunction – UKU1 
      
 Male 15/48 (31%) 14/48 (29%) 15/60 (25%) 16/57 (28%) 19/35 (54%) 0.04 
 Female 11/24 (46%) 21/45 (47%) 18/38 (47%) 10/28 (36%) 11/33 (33%) 0.65 
Weight2       
 Overweight (BMI ≥25) 17/43 (40%) 32/72 (44%) 45/83 (54%) 25/55 (45%) 15/44 (34%) 0.24 
 Weight gain >7% from baseline 23/43 (53%) 45/72 (63%) 71/83 (86%) 36/55 (65%) 17/44 (39%) <0.001 
 Weight change (kg) from baseline       
  Mean (SE) 6.4 (1.0) 8.9 (0.9) 11.6 (0.8) 8.0 (0.9) 4.0 (0.7) <0.001 
  Median (IQR) 5.0 (3.0-10.0) 8.0 (3.0-14.0) 10.0 (7.0-15.0) 6.0 (3.0-12.0) 3.0 (1.0-7.0)  
 Weight change (kg) from baseline / 
month in the study 
      
  Mean (SE) 1.0 (0.2) 1.3 (0.1) 1.7 (0.1) 1.5 (0.2) 0.8 (0.1) <0.001 
  Median (IQR) 0.9 (0.3-1.2) 1.1 (0.5-1.9) 1.5 (1.0-2.3) 1.0 (0.5-2.5) 0.6 (0.3-1.1)  
Electrocardiographic findings       
 Prolonged QTc interval3 1/20 (5%) 1/43 (2%) 3/46 (7%) 2/25 (8%) - 0.61 
Concomitant medication       
 Lithium  -  - 3/105 (3%) 2/104 (2%) - 0.11 
 Mood stabilisers / anticonvulsants 25/103 (24%) 19/104 (18%) 23/105 (22%) 27/104 (26%) 19/82 (23%) 0.74 
 Antidepressants 15/103 (15%) 7/104 (7%) 19/105 (18%) 6/104 (6%) 6/82 (7%) 0.01 
 Hypnotics, sedatives 14/103 (14%) 17/104 (16%) 20/105 (19%) 25/104 (24%) 14/82 (17%) 0.38 
 Anxiolytics 50/103 (50%) 54/104 (52%) 58/105 (55%) 50/104 (48%) 35/82 (43%) 0.51 
 Anticholinergics  37/103 (36%) 29/104 (28%) 18/105 (17%) 21/104 (20%) 17/82 (21%) 0.01 
* Denominators fluctuate due to differences in response. To calculate p-values we did not yet adjust for gender and country. 
1
 Percentages are based on the number of patients with at least one follow-up assessment (SHRS and UKU: 1, 3, 6, 9, 12 months) - cases scored 
positive at at least one evaluation; UKU: cases scored moderate/severe on severity of sexual dysfunction. 
2
 Percentages and change scores are based on the data of patients with at least one post-baseline assessment (3, 6, 9, 12 months) - the maximum 
weight measured during follow-up was selected for the analyses. To convert weight to lb, multiply by 2.2. Body Mass Index (kg/m2); Interquartile 
Range. 
3
 QTc prolongation at 12 months: men >450 mseconds, women >470 mseconds. 
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